{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"DAREON-NEC-1","nct_id":"NCT07544654","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dareon-nec-1-nct07544654. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Treatment arm","label":"Obrixtamig + carboplatin + etoposide","type":"EXPERIMENTAL"},{"description":"Control arm","label":"Carboplatin + etoposide","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-12-13","type":"ESTIMATED"},"conditions":["Extrapulmonary Neuroendocrine Cancer (epNEC)"],"enrollment":{"count":390,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Obrixtamig","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Ventana DLL3 RxDx assay","otherNames":[],"type":"DEVICE"}],"last_update":"2026-10-28","lead_sponsor":"Boehringer Ingelheim","official_title":"A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-12-13","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"Up to 38 months"}],"references":[],"start_date":{"date":"2026-07-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","url":"https://clinicaltrials.gov/study/NCT07544654"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dareon-nec-1-nct07544654"}